PT  - JOURNAL ARTICLE
AU  - B C Figueiredo
AU  - R Sandrini
AU  - G P Zambetti
AU  - R M Pereira
AU  - C Cheng
AU  - W Liu
AU  - L Lacerda
AU  - M A Pianovski
AU  - E Michalkiewicz
AU  - J Jenkins
AU  - C Rodriguez-Galindo
AU  - M J Mastellaro
AU  - S Vianna
AU  - F Watanabe
AU  - F Sandrini
AU  - S B I Arram
AU  - P Boffetta
AU  - R C Ribeiro
TI  - Penetrance of adrenocortical tumours associated with the germline <em>TP53</em> R337H mutation
AID  - 10.1136/jmg.2004.030551
DP  - 2006 Jan 01
TA  - Journal of Medical Genetics
PG  - 91--96
VI  - 43
IP  - 1
4099  - http://jmg.bmj.com/content/43/1/91.short
4100  - http://jmg.bmj.com/content/43/1/91.full
SO  - J Med Genet2006 Jan 01; 43
AB  - Background: An inherited germline P53 mutation has been identified in cases of childhood adrenocortical carcinoma (ACT), a neoplasm with a high incidence in southern Brazil. The penetrance of ACT in carriers of the point mutation, which encodes an arginine-to-histidine substitution at codon 337 of TP53 (R337H), has not been determined. Objective: To investigate the penetrance of childhood ACT in carriers of the R337H TP53 mutation. Methods: The family histories of 30 kindreds of 41 southern Brazilian children with ACT were obtained. A PCR based assay was used to detect this P53 mutation in a large number of relatives of children with ACT. In all, 927 individuals were tested for the mutation, 232 from the non-carrier and 695 (including the 40 probands) from the carrier parental lines. Results: 40 children with ACT carried the TP53 R337H mutation; the remaining child with ACT was not tested. There was no evidence of Li-Fraumeni syndrome in any of the kindreds; however, seven met the criteria for Li-Fraumeni-like syndrome. The carrier parental line was identified in each kindred. Of the 695 individuals tested in the carrier parental line, 240 (34.5%) were positive for the mutation, while none of the 232 individuals in the other parental line carried the mutation. The penetrance of ACT was 9.9% (95% confidence interval, 8.7% to 11.1%). Conclusions: The TP53 R337H mutation dramatically increases predisposition to childhood ACT but not to other cancers, and explains the increased frequency of ACT observed in this geographic region.